Literature DB >> 9588490

Effects of benzodiazepine receptor ligands on the ingestion of sucrose, intralipid, and maltodextrin: an investigation using a microstructural analysis of licking behavior in a brief contact test.

S Higgs1, S J Cooper.   

Abstract

Microstructural analysis of licking behavior in the rat was conducted (a) to describe in detail the characteristics of benzodiazepine-induced changes in ingestion and (b) to determine if the changes are consistent with an alteration in palatability. The effects of the benzodiazepine receptor (BZR) agonist midazolam (0.3-3 mg/kg), and the partial inverse agonist Ro 15-4513 (0.3-3 mg/kg), on licking for several concentrations of sucrose, Intralipid, and maltodextrin in a brief contact test were investigated. Midazolam increased the total number of licks for all 3 fluids; conversely, Ro 15-4513 decreased the total number of licks. Midazolam increased mean bout duration for sucrose and maltodextrin drinking and there was a trend toward a similar effect with Intralipid drinking. Ro 15-4513 reduced mean bout duration for all 3 test fluids. These data are discussed in terms of bidirectional changes in fluid palatability by drug actions at BZRs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588490     DOI: 10.1037//0735-7044.112.2.447

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  10 in total

1.  Nonreinforced flavor exposure attenuates the effects of conditioned taste aversion on both flavor consumption and cue palatability.

Authors:  Dominic Michael Dwyer; Patricia Gasalla; Matías López
Journal:  Learn Behav       Date:  2013-12       Impact factor: 1.986

2.  Multiple processes underlie benzodiazepine-mediated increases in the consumption of accepted and avoided stimuli.

Authors:  D W Pittman; M R McGinnis; L M Richardson; E J Miller; M L Alimohamed; J P Baird
Journal:  Chem Senses       Date:  2012-01-16       Impact factor: 3.160

3.  Analysis of licking microstructure provides no evidence for a reduction in reward value following acute or sub-chronic phencyclidine administration.

Authors:  Emma S Lydall; Gary Gilmour; Dominic M Dwyer
Journal:  Psychopharmacology (Berl)       Date:  2010-02-10       Impact factor: 4.530

4.  Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist.

Authors:  Suzanne Higgs; Alison J Cooper; Nicholas M Barnes
Journal:  Psychopharmacology (Berl)       Date:  2010-12-08       Impact factor: 4.530

5.  Taste neophobia and palatability: the pleasure of drinking.

Authors:  Jian-You Lin; Leslie Renee Amodeo; Joseph Arthurs; Steve Reilly
Journal:  Physiol Behav       Date:  2012-03-29

Review 6.  Conditioned taste aversion, drugs of abuse and palatability.

Authors:  Jian-You Lin; Joe Arthurs; Steve Reilly
Journal:  Neurosci Biobehav Rev       Date:  2014-05-09       Impact factor: 8.989

7.  Microstructural analysis of conditioned and unconditioned responses to maltodextrin.

Authors:  Dominic M Dwyer
Journal:  Learn Behav       Date:  2008-05       Impact factor: 1.986

8.  Pattern of access determines influence of junk food diet on cue sensitivity and palatability.

Authors:  Alisa R Kosheleff; Jingwen Araki; Jennifer Hsueh; Andrew Le; Kevin Quizon; Sean B Ostlund; Nigel T Maidment; Niall P Murphy
Journal:  Appetite       Date:  2017-12-14       Impact factor: 3.868

9.  Differences in the structure of drinking, cart expression and dopamine turnover between polydipsic and non polydipsic rats in the quinpirole model of psychotic polydipsia.

Authors:  Chiara Schepisi; Silvia Cianci; Gaurav Bedse; Jin Fu; Silvana Gaetani; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2014-03-20       Impact factor: 4.530

10.  The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.

Authors:  Suzanne Higgs; Alison J Cooper; Nicholas M Barnes
Journal:  Psychopharmacology (Berl)       Date:  2015-10-28       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.